1 PANTOPRAZOLE SODIUM | 210 of 2090 | 4740 prescriptions Less than 1% of all prescriptions | 4420 | 2250 patients 46% of all patients | 2090 patients 43% of all patients | |
2 OMEPRAZOLE | 1180 of 2150 | 460 prescriptions Less than 1% of all prescriptions | | 230 patients 5% of all patients | < 11 | |
3 BUDESONIDE EC (BUDESONIDE) | 100 of 1050 | 440 prescriptions Less than 1% of all prescriptions | 440 | 140 patients 3% of all patients | 140 patients 3% of all patients | |
4 LINZESS (LINACLOTIDE) | 390 of 1370 | 300 prescriptions Less than 1% of all prescriptions | | 110 patients 2% of all patients | < 11 | |
5 APRISO (MESALAMINE) | 120 of 540 | 350 prescriptions Less than 1% of all prescriptions | 350 | < 11 | < 11 | |
6 AMITIZA (LUBIPROSTONE) | 280 of 700 | 150 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
7 ZENPEP (LIPASE/PROTEASE/AMYLASE) | 30 of 200 | 200 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
8 NADOLOL | 70 of 210 | 150 prescriptions Less than 1% of all prescriptions | 150 | < 11 | < 11 | |
9 GAVILYTE-G (PEG3350/SOD SULF,BICARB,CL/KCL) | 160 of 880 | 760 prescriptions Less than 1% of all prescriptions | | 760 patients 16% of all patients | < 11 | |
10 SUPREP (SODIUM, POTASSIUM,MAG SULFATES) | 280 of 1060 | 1340 prescriptions Less than 1% of all prescriptions | 1200 | 1330 patients 27% of all patients | 1200 patients 25% of all patients | |
11 PENTASA (MESALAMINE) | 90 of 280 | 160 prescriptions Less than 1% of all prescriptions | 160 | < 11 | < 11 | |
12 VEMLIDY (TENOFOVIR ALAFENAMIDE) | 50 of 70 | 120 prescriptions Less than 1% of all prescriptions | 120 | < 11 | < 11 | |
13 PEG-3350 AND ELECTROLYTES (PEG3350/SOD SULF,BICARB,CL/KCL) | 130 of 240 | 120 prescriptions Less than 1% of all prescriptions | 120 | 120 patients 2% of all patients | 120 patients 2% of all patients | |
14 MOVIPREP (PEG3350/SOD SUL/NACL/KCL/ASB/C) | 150 of 240 | 120 prescriptions Less than 1% of all prescriptions | 120 | 120 patients 2% of all patients | 120 patients 2% of all patients | |